

Supplementary Table 2. IBD treatment prior to baseline and treatment changes during primary study period (6 months follow-up)

IBD treatment prior to baseline	All patients (IBD)	Crohn's disease	Ulcerative colitis
Conventional oral treatment, n (%)			
5-aminosalicylic acid	61 (68.5)	24 (50)	37 (90.2)
Azathioprine	76 (85.4)	42 (87.5)	34 (82.9)
6-mercaptopurine	14 (15.7)	8 (16.7)	6 (14.6)
Methotrexate	24 (27.0)	18 (37.5)	6 (14.6)
Systemic corticosteroids ^a	70 (78.7)	34 (70.8)	36 (87.8)
Budesonide	39 (43.8)	27 (56.3)	12 (29.3)
Topical treatment, n (%)			
5-aminosalicylic acid	36 (40.4)	6 (12.5)	30 (73.2)
Corticosteroids ^b	30 (33.7)	9 (18.8)	21 (51.2)
Prior biologic or Janus Kinase inhibitor treatment, n (%)			
Vedolizumab (IV)	89 (100)	48 (100)	41 (100)
Infliximab	70 (78.7)	38 (79.2)	32 (78)
Adalimumab	47 (52.8)	34 (70.8)	13 (31.7)
Ustekinumab	2 (2.2)	2 (4.2)	0 (0.0)
Golimumab	1 (1.1)	1 (2.1)	0 (0.0)
Certolizumab	1 (1.1)	1 (2.1)	0 (0.0)
Natalizumab	1 (1.1)	1 (2.1)	0 (0.0)
Tofacitinib	3 (3.4)	0 (0.0)	3 (7.3)
Changes in treatment during primary study period, n (%)			
Vedolizumab dose optimized (to 108 mg once weekly)	9 (10.1)	6 (12.5)	3 (7.3)
Vedolizumab discontinued	4 (4.5)	0 (0.0)	4 (9.8)
Added			
None	83 (93.3)	44 (91.7)	39 (95.1)
Systemic corticosteroids ^a	3 (3.4)	2 (4.2)	1 (2.4)
Oral budesonide	1 (1.1)	1 (2.1)	0 (0.0)
Topical corticosteroids ^b	3 (3.4)	2 (4.2)	1 (2.4)
Antibiotics	1 (1.1)	1 (2.1)	0 (0.0)
Discontinued			
None	84 (94.4)	47 (97.9)	37 (41)
Oral 5-aminosalicylic acid	3 (3.4)	1 (2.1)	2 (4.9)
Azathioprine	1 (1.1)	0 (0.0)	1 (2.4)
Oral prednisolone	1 (1.1)	0 (0.0)	1 (2.4)
Dose increased			
Oral 5-aminosalicylic acid	1 (1.1)	0 (0.0)	1 (2.4)

^aPrednisolone or betamethasone (oral or iv), ^bprednisolone or budesonide.

Abbreviations: IBD, inflammatory bowel disease; IV, intravenous; n, number of patients.